You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希诺生物(06185.HK)午後股价跌幅收窄至逾8% 指约百万人接种未收到血栓报告
阿思达克 04-14 14:50
阿斯利康(AZN.US)及强生(JNJ.US)研发的新冠疫苗先後出现怀疑血栓病例。康希诺生物-B(06185.HK)今日盘中曾低见255.2元一度下挫18.4%,公司中午发自愿公告指其与阿斯利康新冠疫苗所使用的黑猩猩腺病毒载体和强生新冠疫苗所使用的26型腺病毒载体不同,康希诺生物午後股价跌幅略为收窄,最新报286.8元下跌8.3%。

康希诺生物中午公布,公司注意到部分媒体有关接种阿斯利康新冠疫苗和强生新冠疫苗後个人出现罕见和严重血栓病例有关的报道。公司指,重组新型冠状病毒疫苗(5型腺病毒载体)(「Ad5-nCoV」)的载体为5型腺病毒,一种常见的感染人的腺病毒,与阿斯利康新冠疫苗所使用的黑猩猩腺病毒载体和强生新冠疫苗所使用的26型腺病毒载体不同。

截至今日中午止,接种Ad5-nCoV的约百万人中未收到与血栓相关的严重不良事件的报告。公司将密切关注相关情况并根据香港联合交易所有限公司证券上市规则的规定在适当的时候作出进一步的公告。(wl/k)

~

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account